Elevation Oncology Presents Preclinical Proof-Of-Concept Data For HER3-ADC Program At AACR Annual Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Elevation Oncology, Inc. (NASDAQ:ELEV) announced preclinical proof-of-concept data for its HER3-ADC program at the AACR Annual Meeting 2024. The data demonstrates the program's potential in treating HER3-expressing cancers with a novel antibody-drug conjugate (ADC) that selectively targets HER3. The company plans to nominate a development candidate later in 2024, aiming to advance this therapy closer to clinical trials. The HER3-ADC program, which includes the molecule HER3-ADC1, showed promising results in vitro and in vivo, outperforming a benchmark HER3-ADC in cytotoxicity assays and inducing tumor regression in a pancreatic cancer model.
April 08, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevation Oncology's announcement of promising preclinical data for its HER3-ADC program could positively impact its stock price in the short term. The data, presented at the AACR Annual Meeting 2024, demonstrates the potential of the company's novel ADC in treating HER3-expressing cancers, a significant step towards clinical trials.
The positive preclinical data for ELEV's HER3-ADC program indicates a significant advancement in its oncology pipeline, which could attract investor interest and potentially lead to an increase in stock price. The announcement of moving closer to nominating a development candidate later this year further strengthens the company's position in the oncology sector, making this news highly relevant and important for investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100